Opportunity Information: Apply for PA 06 371
Apply for PA 06 371
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "In vivo Cancer Imaging Exploratory/Developmental Grants (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 27, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments County governments Special district governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The In vivo Cancer Imaging Exploratory/Developmental Grants (R21) opportunity (Funding Opportunity Number PA 06 371) is an NIH discretionary grant program run through the National Institutes of Health, specifically the Cancer Imaging Program (CIP) within the Division of Cancer Treatment and Diagnosis (DCTD). Its purpose is to support exploratory, early stage research in in vivo cancer imaging that is either high risk (ideas that may be technically challenging or unproven but could open up new directions) or high impact (work that could meaningfully improve how cancers are found, characterized, or tracked during treatment). The scientific focus is firmly on imaging performed in living systems, with an emphasis on practical advances that could influence cancer detection, diagnosis, and monitoring of response to therapy.
The scope is intentionally broad across the full pipeline of in vivo cancer imaging innovation. Projects can range from basic discovery, such as inventing or identifying new imaging agents (for example, probes, tracers, contrast agents, or targeted molecular reporters) and new imaging technologies or methods, all the way through preclinical testing and validation. The announcement also supports early feasibility evaluation of promising new imaging agents and technologies in small clinical trials, meaning applicants can propose limited, early human studies when justified and appropriate for an R21 stage. Overall, the FOA is meant to help investigators generate the kind of compelling preliminary evidence that can de risk a bold concept and position it for later, larger scale funding and validation.
This program uses only the NIH R21 mechanism, which is designed for exploratory and developmental work rather than mature, fully validated programs. A key structural point is that R21 awards under this FOA are not renewable, so applicants should plan a focused set of aims that can realistically be completed within the allowed timeline. The maximum project period is 2 years. Budget limits are set at up to 275,000 in direct costs across the two year period, with an additional constraint that no more than 200,000 in direct costs may be requested in any single year. There is no cost sharing or matching requirement. Because imaging projects can differ widely in complexity and resource needs, the NIH notes that award sizes and durations within the two year cap may vary, and the actual number of awards and total dollars awarded depend on application quality, scientific merit, project length, and proposed costs.
Eligibility is expansive and includes a wide variety of organization types. Eligible applicants include for profit and nonprofit organizations; public or private institutions such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible federal government institutions; and community based or faith based organizations. Tribal entities are explicitly included, covering federally recognized and other than federally recognized Indian/Native American Tribal Governments as well as Indian/Native American tribally designated organizations. Foreign institutions are also eligible to apply, which is notable because not all NIH opportunities allow foreign organizational applicants.
The program is open to any qualified Project Director/Principal Investigator. NIH does not restrict who may serve as PD/PI beyond having the expertise, resources, and institutional support to carry out the proposed work. The announcement specifically encourages applications from individuals from underrepresented racial and ethnic groups and from individuals with disabilities, consistent with NIH wide goals around broad participation in biomedical research. Multiple applications may be submitted by the same applicant as long as each submission is scientifically distinct, meaning they must propose meaningfully different research questions, approaches, or projects rather than variations of the same idea.
Administratively, the FOA was posted April 27, 2006, and uses multiple receipt dates (rolling or recurring deadlines depending on NIH schedules listed in the full announcement). The CFDA program areas associated with it are 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). The announcement lists an award ceiling of 200,000, while the broader R21 budget guidance in the text allows up to 275,000 direct costs over two years with a per year cap; applicants typically need to follow the FOA specific instructions and NIH policy and align their budget with both the two year total and the single year maximums. Full details and any receipt date specifics are provided in the official NIH Grants Guide posting at http://grants.nih.gov/grants/guide/pa-files/PA-06-371.html, with technical access support through the NIH Office of Extramural Research webmaster contacts listed in the notice.
Frequently Asked Questions (FAQs)
What is the In vivo Cancer Imaging Exploratory/Developmental Grants (R21) opportunity?
It is an NIH discretionary grant program supporting exploratory and early stage research in in vivo cancer imaging. The opportunity is titled "In vivo Cancer Imaging Exploratory/Developmental Grants (R21)" and is published as Funding Opportunity Number PA-06-371.
Which NIH office runs this funding opportunity?
The program is run through the National Institutes of Health (NIH), specifically the Cancer Imaging Program (CIP) within the Division of Cancer Treatment and Diagnosis (DCTD).
What is the main purpose of this FOA?
The purpose is to support exploratory, early stage in vivo cancer imaging research that is high risk (technically challenging or unproven ideas that could open new directions) or high impact (work that could meaningfully improve how cancers are detected, characterized, or monitored during treatment).
What does "in vivo cancer imaging" mean in the context of this opportunity?
The scientific focus is on imaging performed in living systems, with an emphasis on practical advances that could influence cancer detection, diagnosis, and monitoring response to therapy.
What kinds of projects are in scope for PA-06-371?
The scope is intentionally broad across the pipeline of in vivo cancer imaging innovation. Projects may include basic discovery (such as inventing or identifying new imaging agents) through preclinical testing and validation, and may also include early feasibility evaluation in small clinical trials when justified and appropriate for the R21 stage.
What are examples of imaging agents that could be supported?
The FOA describes imaging agents such as probes, tracers, contrast agents, or targeted molecular reporters.
Does the FOA support new imaging technologies or methods?
Yes. In addition to imaging agents, the announcement supports development of new imaging technologies or methods, along with preclinical testing and validation.
Are clinical studies allowed under this R21 opportunity?
Yes, the announcement supports early feasibility evaluation of promising new imaging agents and technologies in small clinical trials. These are limited, early human studies when justified and appropriate for an R21 stage project.
What is the funding mechanism used for this program?
This program uses the NIH R21 mechanism only, which is intended for exploratory and developmental work rather than mature, fully validated programs.
Can an R21 award under this FOA be renewed?
No. A key structural point is that R21 awards under this FOA are not renewable. Applicants are expected to plan focused aims that can realistically be completed within the allowed timeline.
What is the maximum project period?
The maximum project period is 2 years.
What are the budget limits for this opportunity?
Budget limits are up to $275,000 in direct costs total across the two-year period, with an additional constraint that no more than $200,000 in direct costs may be requested in any single year.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
Will all awards be the same size and duration?
No. NIH notes that award sizes and durations within the two-year cap may vary because imaging projects can differ widely in complexity and resource needs.
How is the number of awards determined?
The actual number of awards and total dollars awarded depend on application quality, scientific merit, project length, and proposed costs.
Who is eligible to apply as an organization?
Eligibility is broad. Eligible applicants include for-profit and nonprofit organizations; public or private institutions such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible federal government institutions; and community-based or faith-based organizations.
Are Tribal entities eligible to apply?
Yes. Tribal entities are explicitly included, covering federally recognized Indian/Native American Tribal Governments, other than federally recognized Indian/Native American Tribal Governments, and Indian/Native American tribally designated organizations.
Are foreign institutions eligible to apply?
Yes. Foreign institutions are eligible to apply under this opportunity, which is notable because not all NIH opportunities allow foreign organizational applicants.
Who can serve as the Project Director/Principal Investigator (PD/PI)?
The program is open to any qualified PD/PI. NIH does not restrict who may serve as PD/PI beyond having the expertise, resources, and institutional support to carry out the proposed work.
Does the FOA encourage applications from specific groups of investigators?
Yes. The announcement specifically encourages applications from individuals from underrepresented racial and ethnic groups and from individuals with disabilities.
Can the same applicant submit more than one application?
Yes. Multiple applications may be submitted by the same applicant as long as each submission is scientifically distinct, meaning the projects must be meaningfully different rather than variations of the same idea.
When was this FOA posted?
The FOA was posted on April 27, 2006.
Are there multiple deadlines or receipt dates?
Yes. The opportunity uses multiple receipt dates, described as rolling or recurring deadlines depending on the NIH schedules listed in the full announcement.
What CFDA program areas are associated with this opportunity?
The CFDA program areas associated with this FOA are 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research).
I see an award ceiling of $200,000 mentioned. How does that relate to the R21 budget guidance?
The announcement lists an award ceiling of $200,000, while the broader R21 budget guidance in the text allows up to $275,000 in direct costs over two years with a per-year cap. Applicants typically need to follow FOA-specific instructions and NIH policy and align budgets with both the two-year total and the single-year maximums.
Where can I find the official posting and full details?
The official NIH Grants Guide posting is available at http://grants.nih.gov/grants/guide/pa-files/PA-06-371.html.
Where can applicants get technical access support for the NIH posting?
The notice indicates that technical access support is available through the NIH Office of Extramural Research webmaster contacts listed in the posting.
Browse more opportunities from the same category: Education Health
Next opportunity: Women s Mental Health in Pregnancy and the Postpartum Period (R21)
Previous opportunity: Proteomics in Auditory Developmental and Disease Processes (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 06 371
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 06 371) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Surveillance Using Health Claims based Data System (R21) Apply for PA 06 386 Funding Number: PA 06 386 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Developmental Projects in Complementary Approaches to Cancer Care (R21) Apply for PA 06 400 Funding Number: PA 06 400 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Studies of Energy Balance and Cancer in Humans (R21) Apply for PA 06 405 Funding Number: PA 06 405 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33) Apply for PA 06 434 Funding Number: PA 06 434 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phase II Developmental Research in Cancer Prognosis and Prediction (R33) Apply for PA 06 435 Funding Number: PA 06 435 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development of Frontal Cortex and Limbic System and their roles in Drug Abuse or Mental Health (R21) Apply for PA 06 445 Funding Number: PA 06 445 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) Apply for PAR 06 476 Funding Number: PAR 06 476 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral and Integrative Treatment Development Program (R21) Apply for PA 06 487 Funding Number: PA 06 487 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 06 488 Funding Number: PA 06 488 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) Apply for PA 06 496 Funding Number: PA 06 496 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) Apply for PA 06 497 Funding Number: PA 06 497 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis(R21) Apply for PA 06 499 Funding Number: PA 06 499 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R03) Apply for PA 06 502 Funding Number: PA 06 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R21) Apply for PA 06 501 Funding Number: PA 06 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute (NCI) Cancer Education and Career Development Program (R25) Apply for PAR 06 511 Funding Number: PAR 06 511 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 06 461 Funding Number: PA 06 461 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33) Apply for PA 06 462 Funding Number: PA 06 462 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PA 06 463 Funding Number: PA 06 463 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 06 520 Funding Number: PAR 06 520 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 06 521 Funding Number: PAR 06 521 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 371", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.